missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ NOXA Polyclonal Antibody

Descripción
A suggested positive control is human stomach tissue lysate. PA5-19977 can be used with blocking peptide PEP-0305.
Apoptosis is related to many diseases and development. The p53 tumor-suppressor protein induces apoptosis through transcriptional activation of several genes including p53R2, p53AIP1, and PUMA. A new p53 target gene, Noxa, was recently identified, which encodes a protein belonging to the subfamily of BH3-only proapoptic proteins. Noxa and PUMA are both transcriptional targets of p53 and BH3-only proteins. X-ray irradiation increased p53-dependent Noxa mRNA and protein levels. Noxa, when ectopically expressed, interacted with anti-apoptotic Bcl-2 family members, resulting in the activation of caspase-9. Noxa, like PUMA, localized to mitochondria and induces apoptosis in response to p53. Noxa and PUMA may represent direct mediators of p53-induced apoptosis. Increased levels of p53 and its target gene Noxa was found in the impaired tumor development.
Especificaciones
Especificaciones
| Antígeno | NOXA |
| Aplicaciones | Immunohistochemistry, Western Blot, Immunocytochemistry |
| Clasificación | Polyclonal |
| Concentración | 1 mg/mL |
| Conjugado | Unconjugated |
| Formulación | PBS with 0.02% sodium azide |
| génica | PMAIP1 |
| N.º de referencia del gen | Q13794, Q5U777, Q9JM54 |
| Alias de gen | adult T cell leukemia-derived PMA-responsive; APR; Immediate-early-response protein APR; Noxa; Phorbol-12-myristate-13-acetate-induced protein 1; PMA-ind; PMA-induced protein 1; Pmaip1; Protein Noxa |
| Símbolos de los genes | PMAIP1 |
| Mostrar más |
Título del producto
Al hacer clic en Enviar, acepta que Fisher Scientific se ponga en contacto con usted en relación con los comentarios que ha proporcionado en este formulario. No compartiremos su información para ningún otro fin. Toda la información de contacto proporcionada se mantendrá de acuerdo con nuestra Política de Privacidad. Política de privacidad.
¿Detecta una oportunidad de mejora?